Medical News Today: Vision loss in glaucoma may be due to immune response
Glaucoma is a condition that leads to progressive loss of vision, but its root causes remain unclear. New research says an immune response may be to blame. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 14, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

ME & MY OPERATION: The tap in the eye that could stop glaucoma patients from losing their sight
Glaucoma affects 300,000 people in the UK and is a leading cause of blindness. Here, Bernie Pedley, 73, from Preston, Lancashire, tells her story of life-changing surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2018 Category: Consumer Health News Source Type: news

Ivantis Now Has Its MIGS Stent Approved
The competition in the microinvasive glaucoma surgical (MIGS) space is certainly heating up after today’s news. FDA has given a nod to Ivantis’ Hydrus Microstent, which will undoubtedly compete against Glaukos’ iStent. Irvine,CA-based Ivantis’ approval comes on the heels of Glaukos winning a nod from FDA for the iStent inject Trabecular Micro-Bypass System. The Hydrus Microstent is used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The device’s approval is based on the HORIZO...
Source: MDDI - August 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

FDA approves Ivantis ’ Hydrus microstent
Ivantis said today it won FDA approval for its Hydrus microstent designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with glaucoma. The device is multi-modal, the company said, by creating a large opening through the trabecular meshwork and dilating and scaffolding the conventional pathway through which fluid exits the eye. Approval came based on results from the Horizon trial, which the Irvine, Calif.-based company touted as the largest min...
Source: Mass Device - August 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Ivantis Source Type: news

New Research Suggests Glaucoma May Be an Autoimmune Disease
Title: New Research Suggests Glaucoma May Be an Autoimmune DiseaseCategory: Health NewsCreated: 8/10/2018 12:00:00 AMLast Editorial Review: 8/13/2018 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - August 13, 2018 Category: Opthalmology Source Type: news

Study Links 3 Eye Diseases, Alzheimer's
Patients with age-related macular degeneration, diabetic retinopathy or glaucoma had a 40 to 50 percent greater risk of Alzheimer's disease than those without the eye conditions, the authors of a new study report. (Source: WebMD Health)
Source: WebMD Health - August 12, 2018 Category: Consumer Health News Source Type: news

New Research Suggests Glaucoma May Be an Autoimmune Disease
FRIDAY, Aug. 10, 2018 -- The eye disease glaucoma may be an autoimmune disorder, a new study suggests. Glaucoma affects nearly 70 million people worldwide. It damages the retina and optic nerve and can lead to blindness. In research with mice,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 10, 2018 Category: General Medicine Source Type: news

Study suggests glaucoma may be an autoimmune disease
(Massachusetts Institute of Technology) A new study from MIT and Massachusetts Eye and Ear finds glaucoma may be an autoimmune disorder, mediated by T cells that target heat shock proteins in the retina. The discovery suggests it could be possible to develop new treatments for glaucoma by blocking this autoimmune activity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 10, 2018 Category: International Medicine & Public Health Source Type: news

Autoimmune response drives vision loss in glaucoma
(Massachusetts Eye and Ear Infirmary) A research team from Massachusetts Eye and Ear and MIT has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in the world. The findings, published online in Nature Communications, suggest that high pressure in the eye leads to vision loss by setting into motion an autoimmune response that attacks the neurons in the eye. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 10, 2018 Category: International Medicine & Public Health Source Type: news

Have Glaucoma and Need to Switch Eye Docs? Here's What You Need to Do
Title: Have Glaucoma and Need to Switch Eye Docs? Here's What You Need to DoCategory: Health NewsCreated: 8/7/2018 12:00:00 AMLast Editorial Review: 8/8/2018 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - August 8, 2018 Category: Opthalmology Source Type: news

Eye conditions provide new lens screening for Alzheimer's disease
(University of Washington Health Sciences/UW Medicine) A study of 3,877 randomly selected patients found a significant link between three degenerative eye diseases -- age-related macular degeneration, diabetic retinopathy and glaucoma -- and Alzheimer' disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 8, 2018 Category: International Medicine & Public Health Source Type: news

Are The Health Benefits Of Turmeric Too Good To Be True?
(CNN) — Alzheimer’s disease. Diabetes. Arthritis. Unwanted hair growth. Baldness. Infertility. Erectile dysfunction. Hangovers. Glaucoma. Cancer. If you have an ailment, there’s a good chance that someone, somewhere, is studying whether turmeric can treat it. There are more than 15,000 manuscripts published about curcumin, the active ingredient in turmeric, and about 50 manuscripts added to this collection each week, according to the National Institutes of Health. “It’s really taken on sort of panacea-like properties in terms of the things it’s being studied for and the things it has bee...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 7, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local TV turmeric Source Type: news

Have Glaucoma and Need to Switch Eye Docs? Here's What You Need to Do
TUESDAY, Aug. 7, 2018 -- If you have glaucoma and need to find a new ophthalmologist, creating a personal data portfolio will help ensure a smooth transition in the care of your eye disease. The Glaucoma Research Foundation suggests the portfolio... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2018 Category: General Medicine Source Type: news

Glaukos inks R & D deal for glaucoma therapy
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos inks R&D deal for glaucoma therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Research & Development Wall Street Beat Glaukos Source Type: news

American Academy of Ophthalmology launches new scientific journal dedicated to glaucoma research
(American Academy of Ophthalmology) The American Academy of Ophthalmology today announced the launch of Ophthalmology ® Glaucoma, a new scientific journal focused exclusively on glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2018 Category: International Medicine & Public Health Source Type: news

Durham pharma could be on its way to second FDA approval
Durham-based Aerie Pharmaceuticals (Nasdaq: AERI) could be well on its way to a second U.S. Food and Drug Administration approval.   The FDA has accepted Aerie’s new drug application (NDA) submission for the company’s second glaucoma drug, Roclatan, earlier than expected.  Aerie said this week that the FDA has set a goal date for completion of the agency’s review of the Roclatan NDA of March 14, 2019. The NDA acceptan ce comes less than three months after Aerie said it had launched its first… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 26, 2018 Category: Health Management Authors: Jennifer Henderson Source Type: news

Durham pharma could be on its way to second FDA approval
Durham-based Aerie Pharmaceuticals (Nasdaq: AERI) could be well on its way to a second U.S. Food and Drug Administration approval.   The FDA has accepted Aerie’s new drug application (NDA) submission for the company’s second glaucoma drug, Roclatan, earlier than expected.  Aerie said this week that the FDA has set a goal date for completion of the agency’s review of the Roclatan NDA of March 14, 2019. The NDA acceptan ce comes less than three months after Aerie said it had launched its first… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 26, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Turmeric extract in eye drops could treat the early stages of glaucoma
Curcumin, extracted from the yellow spice turmeric, could be used in eye drops to treat the early stages of glaucoma, found a new study led by MRC-funded researchers. (Source: Medical Research Council General News)
Source: Medical Research Council General News - July 25, 2018 Category: Research Source Type: news

How turmeric could offer hope for millions with glaucoma
University College London and Imperial College London trials showed eye drops containing curcumin, responsible for turmeric's yellow colour, slashed the loss of crucial retinal cells in rats. (Source: the Mail online | Health)
Source: the Mail online | Health - July 25, 2018 Category: Consumer Health News Source Type: news

Medical News Today: How a turmeric compound could treat glaucoma
Glaucoma can lead to vision loss, but a turmeric derivative can improve current treatments. New research devises a viable method of adding it to eye drops. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 25, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Turmeric derivative in drops may treat glaucoma
Adding an extract from the yellow spice turmeric into eye drops was effective in treating early stages of glaucoma in a study with rats. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 24, 2018 Category: Consumer Health News Source Type: news

Turmeric eye drops could treat glaucoma
(University College London) A derivative of turmeric could be used in eye drops to treat the early stages of glaucoma, finds a new study led by UCL and Imperial College London researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 23, 2018 Category: International Medicine & Public Health Source Type: news

Gene regulator may contribute to protein pileup in exfoliation glaucoma
(Medical College of Georgia at Augusta University) In exfoliation glaucoma, a protein dandruff clogs the outflow pathway for the fluid in our eyes.Scientists have evidence that variants of the same gene that enables us to make connective tissue by crosslinking proteins is associated with this unusual glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2018 Category: International Medicine & Public Health Source Type: news

Pfizer Hikes Cost Of Viagra And 100 Other Drugs, Report Says
(CBS News) — A month after President Donald Trump signaled drug companies would soon be slashing prices, the nation’s largest pharmaceutical company is reportedly upping the costs of 100 drugs and treatments. Pfizer has increased the price of some of its better-known drugs, including the erectile dysfunction treatment Viagra, according to a story published Monday by the Financial Times. The increases, which took effect July 1, are just over 9 percent on average, well above the rate of inflation, which is about 2 percent. It’s the second such move this year by Pfizer, with the cost of some of its drugs up ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 2, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Local TV Pfizer Source Type: news

Novartis and Alcon to Separate
Novartis said it plans to spin out its Alcon Division into a separately-traded company. The move will allow the Basel, Switzerland-based company and Alcon to focus on respective growth strategies. If the split meets general market conditions, regulatory approvals, final Board of Directors endorsement, and shareholder approval then the planned separation could be completed by the first half of 2019. Novartis said if the Alcon spin out is completed, then it would create a new Switzerland-based company with global scale and reach comprising more than 20,000 employees, with around $7 billion in 2017 sales. The firm said that i...
Source: MDDI - June 29, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Glaucoma Surgery Space Heats Up with New Approval
Glaukos has received FDA approval to market the iStent inject Trabecular Micro-Bypass System. The nod gives the San Clementa, CA-based company an opportunity to pull ahead of competition in the minimally invasive glaucoma surgery (MIGS) market. Glaukos said the iStent inject is designed to optimize the natural physiological outflow of aqueous humor by creating two patent bypasses through the trabecular meshwork, the main source of resistance in glaucomatous eyes, resulting in multi-directional flow through Schlemm’s canal. It includes two heparin-coated titanium stents preloaded into an auto-injection syst...
Source: MDDI - June 25, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Glaukos wins FDA PMA for iStent inject glaucoma device
Glaukos (NYSE:GKOS) said today it won FDA premarket approval for its iStent inject trabecular micro-bypass system. With the clearance, the iStent inject is now indicated for use in the reduction of intraocular pressure in adults with mild to moderate primary open-angle glaucoma who are undergoing concomitant cataract surgery. San Clemente, Calif.-based Glaukos said the iStent inject is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecu...
Source: Mass Device - June 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Pre-Market Approval (PMA) Regulatory/Compliance Glaukos Source Type: news

Medical News Today: Persistent stress may lead to vision loss, study shows
A new analysis of existing studies shows that persistent psychological stress can lead to conditions such as glaucoma, retinal neuropathy, and vision loss. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

A stressful job could leave you blind: Psychological pressure can cause vision loss, scientists warn
Stress can bring on or worsen vision problems and even lead to blindness because of conditions like glaucoma and diabetes, according to research by Magdeburg University in Germany. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2018 Category: Consumer Health News Source Type: news

UH scientist working toward a glaucoma cure
(University of Houston) With $765,000 from the National Institutes of Health, University of Houston College of Optometry biomedical engineer Vijaykrishna Raghunathan is working towards a pharmaceutical cure for the irreversible disease Glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 19, 2018 Category: International Medicine & Public Health Source Type: news

' Promising Option' for IOP Reduction'Promising Option' for IOP Reduction
A review of the study that led to the recent approval of latanoprostene bunod for open-angle glaucoma and ocular hypertension.Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2018 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news

As Glaucoma Patients Lose Visual Field, They Lose Driving Skills As Glaucoma Patients Lose Visual Field, They Lose Driving Skills
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

More than 20 people go blind a month in the UK due to delayed and cancelled hospital appointments
More than half of the people in the UK suffering from treatable conditions such as wet age-related macular degeneration and glaucoma, have had an appointment postponed or cancelled at least once. (Source: the Mail online | Health)
Source: the Mail online | Health - June 6, 2018 Category: Consumer Health News Source Type: news

Don ’t risk this sight-stealing condition
This National Glaucoma Week (4-10 June 2018), the Association of Optometrists (AOP) is highlighting the importance of regular eye health checks in detecting sight-threatening conditions such as glaucoma – warning that the signs often go unnoticed. (Source: NHS Networks)
Source: NHS Networks - May 31, 2018 Category: UK Health Source Type: news

FDA Approves First Artificial Iris
A German company has become the first to score FDA approval for a stand-alone prosthetic iris in the United States. The agency said Wednesday afternoon that it approved the CustomFlex Artificial Iris, made by Erlangen, Germany-based HumanOptics. The device, which is surgically implanted, is approved to treat adults and children whose iris is completely missing or damaged due to a congenital condition called aniridia or other damage to the eye. “Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye,” said Malvina Eydelman, MD, dire...
Source: MDDI - May 30, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

How a San Francisco nonprofit's vision for glaucoma research is gaining new insights, cash
Researchers funded by the Glaucoma Research Foundation may never have focused on the blinding eye disease. But as the foundation begins to assemble its third team of researchers, and as funders pushed it to extend its capital campaign to $25 million, its CEO is confident a cure may come soon. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 29, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

How a San Francisco nonprofit's vision for glaucoma research is gaining new insights, cash
Researchers funded by the Glaucoma Research Foundation may never have focused on the blinding eye disease. But as the foundation begins to assemble its third team of researchers, and as funders pushed it to extend its capital campaign to $25 million, its CEO is confident a cure may come soon. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 29, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Scientists seek to better protect the eye from glaucoma
(Medical College of Georgia at Augusta University) Under the increased pressure of glaucoma, scientists want to help the neurons in our eyes better protect themselves and get better help from their friends.They are working to see whether agents that activate the innate neuron protector sigma 1 receptor, or S1R, can do both. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2018 Category: International Medicine & Public Health Source Type: news

DNA test to predict glaucoma
THE chances of a person developing glaucoma could soon be picked up at birth after scientists identified the genetic risk factors behind the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 23, 2018 Category: Consumer Health News Source Type: news

Aerie submits second drug for FDA approval
Aerie Pharmaceuticals has submitted its second glaucoma drug, Roclatan, to the U.S. Food and Drug Administration for potential approval. Aerie said Tuesday that it expects the FDA review period for Roclatan to be just 10 months rather than the typical 12 months because Roclatan is a fixed-dose combination of two drugs previously approved in the U.S. The move follows the commercial launch of its first drug approved by the FDA, know n as Rhopressa. The FDA approved that drug in December – two months… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 15, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

Butterfly wing inspires design of glaucoma sensor
Inspired by a clear butterfly wing, researchers designed a tiny implantable sensor to measure eye pressure. With further development, it could be tested in people. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 15, 2018 Category: Consumer Health News Source Type: news

The keto diet protects your eyesight
To so-called keto diet has shown to ease seizures in epilepsy patients. Now a study has found the slimming celebrity diet could also lower the risk of glaucoma, the leading cause of blindness. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2018 Category: Consumer Health News Source Type: news

Locations, circumstances, and outcomes of falls in patients with glaucoma - Sotimehin AE, Yonge AV, Mihailovic A, West SK, Friedman DS, Gitlin LN, Ramulu PY.
PURPOSE: To characterize the locations, circumstances, and outcomes of falls in patients with varying degrees of glaucoma. DESIGN: Prospective cohort study METHODS: Patients with suspected or diagnosed glaucoma completed monthly calendars reporting... (Source: SafetyLit)
Source: SafetyLit - May 14, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Glaucoma Device Makers See a Bright Future Ahead
Were The Graduate's Ben Braddock to receive a one-word bit of career advice today, it might very well be "MIGS" instead of plastics. MIGS stands for minimally invasive glaucoma surgery, and both financial analysts and developers of the tiny devices designed to treat the disease expect the market to pop for the foreseeable future. "On a scale of one through 10, I would say the market is probably somewhere between one and two in terms of maturity," said Dave Van Meter, CEO of Irvine, CA-based Ivantis. "The market in the U.S. today is probably somewhere around a couple hundred million dollars, ac...
Source: MDDI - May 11, 2018 Category: Medical Devices Authors: Greg Goth Tags: Implants Source Type: news

With $334M in cash, Aerie preps to break even
With $334 million in cash, equivalents and investments as of March 31 and its first drug launched, Durham ’s Aerie Pharmaceuticals is prepped to break even. The company (Nasdaq: AERI) confirmed Tuesday that its current cash is sufficient to get it to its break-even point on its first quarter financial results call. After hiring and training a 100-person sales force, Aerie’s glaucoma drug Rhopressa officially launched last week in national and regional pharmaceutical distributors in the U.S. “We… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 9, 2018 Category: Health Management Authors: Jennifer Henderson Source Type: news

With $334M in cash, Aerie preps to break even
With $334 million in cash, equivalents and investments as of March 31 and its first drug launched, Durham ’s Aerie Pharmaceuticals is prepped to break even. The company (Nasdaq: AERI) confirmed Tuesday that its current cash is sufficient to get it to its break-even point on its first quarter financial results call. After hiring and training a 100-person sales force, Aerie’s glaucoma drug Rhopressa officially launched last week in national and regional pharmaceutical distributors in the U.S. “We… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 9, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Aerie launches glaucoma drug in U.S.
Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision. Get the full story at our sister site, Drug Delivery Business News. The post Aerie launches glaucoma drug in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

UMKC lands $1.97M grant for glaucoma treatment
Researchers at the University of Missouri-Kansas City School of Medicine landed $1.937 million to develop a way to treat patients with end-stage glaucoma. The five-year grant from the National Institutes of Health will support principal investigator Karl Kador's research on ways to restore vision to patients with glaucoma and other eye disorders. Kador, an assistant professor of ophthalmology and biomedical sciences, studies disease and injuries that lead to the death of retinal ganglion cells,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 26, 2018 Category: American Health Authors: Elise Reuter Source Type: news

French pharma moves U.S. base to RTP from Texas
French pharmaceutical company Nicox has opened its new U.S. development office in Research Triangle Park, moving it from Fort Worth, Texas. The opening of the office comes as Nicox is looking to begin phase 2 clinical studies of product candidates for glaucoma and blepharitis – an inflammation of the eyelid. In the Triangle area, Nicox was able to hire all of the team members it needed to get started within a month, says Gavin Spen cer, executive vice president and chief business officer. The… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 25, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

French pharma moves U.S. base to RTP from Texas
French pharmaceutical company Nicox has opened its new U.S. development office in Research Triangle Park, moving it from Fort Worth, Texas. The opening of the office comes as Nicox is looking to begin phase 2 clinical studies of product candidates for glaucoma and blepharitis – an inflammation of the eyelid. In the Triangle area, Nicox was able to hire all of the team members it needed to get started within a month, says Gavin Spen cer, executive vice president and chief business officer. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news